Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ascorbate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Standard of Care Group | ACTIVE_COMPARATOR | carboplatin and paclitaxel chemotherapy |
| Standar of Care + Ascorbic Acid Group | EXPERIMENTAL | carboplatin and paclitaxel chemotherapy, plus intravenous sodium ascorbate. In addition, participants will take a mix of vitamins including oral ascorbic acid, oral mixed natural carotenoids with vitamin A and oral vitamin E. |
| Name | Type | Description |
|---|---|---|
| Oral Ascorbic Acid | DIETARY_SUPPLEMENT | 4 grams per day for 12 months |
| Paclitaxel | DRUG | Six cycles |
| Carboplatin | DRUG | Six cycles |
| Sodium Ascorbate | DRUG | Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months |
| Oral Mixed natural Carotenoids with Vitamin A | DIETARY_SUPPLEMENT | Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months |
| Vitamin E | DIETARY_SUPPLEMENT | 500 IU per capsule and participant to take 1 capsule daily for 12 months |
Inclusion Criteria: * histologically confirmed carcinoma of the ovary stage III or IV * measurable or assessable disease * drug refractory ovarian cancer * must be 18 years of age or must have parental consent to enroll in the study * must be ambulatory Exclusion Criteria: * evidence of significa...
Top 20 of 59 competitors
Ascorbate is an investigational small molecule being studied for the treatment of ovarian cancer. It is currently in Phase 1 clinical development, with one completed trial involving 27 participants in the United States. The drug is being developed by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP).
Ascorbate is being developed by CNS Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker CNSP. The company is conducting clinical research on this investigational small molecule for ovarian cancer, with a completed Phase 1 trial in the United States.
Ascorbate is in Phase 1 clinical development for ovarian cancer. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 27 female participants aged 18 years and older in the United States.
Ascorbate has one completed clinical trial, identified as NCT00228319, titled "Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants." This Phase 1 study enrolled 27 participants with ovarian cancer in the United States. The trial was active-controlled and randomized, though it was not double-blinded.
Ascorbate is a form of vitamin C, also known as ascorbic acid. In the context of this clinical research, it is being investigated as a potential treatment for ovarian cancer. The drug is in Phase 1 development by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP).